<DOC>
	<DOCNO>NCT00787527</DOCNO>
	<brief_summary>The goal clinical research study find well drug Zolinza ( vorinostat ) work combination drug combination call CHOP ( cyclophosphamide , doxorubicin , vincristine , prednisone ) treat patient untreated T-cell Non-Hodgkin 's Lymphoma ( NHL ) . The safety drug combination best dose vorinostat give combination CHOP also study .</brief_summary>
	<brief_title>SAHA + CHOP Untreated T-cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>The Study Drugs : Vorinostat design cause chemical change different group protein attach DNA ( genetic material cell ) , may slow growth cancer cell cause cancer cell die . Cyclophosphamide design interfere multiplication cancer cell , may slow stop growth . This may cause cancer cell die . Doxorubicin design stop growth cancer cell , may cause cell die . Vincristine design interfere multiplication cancer cell , may slow stop growth . This may cause cancer cell die . Prednisone design decrease inflammation prevent white blood cell complete inflammatory reaction . This drug cause lymphocytes , type white blood cell , break apart die . Study Drug Administration : If find eligible take part study , begin take vorinostat first day treatment Day -1 . Vorinostat capsule take mouth , either 3 time day 2 time day , depend study doctor think best interest . If take vorinostat 3 time day , take morning , afternoon evening . If take vorinostat 2 time day , take capsule morning evening . The capsule must take food ( within 30 minute meal ) . You receive vorinostat capsule first day cycle . You also receive instruction take drug . You return unused vorinostat capsule back study staff end cycle . You take vorinostat 5 day ( Days -1 3 ) cycle begin Day 1 , cyclophosphamide , vincristine , doxorubicin give though needle vein . This happen 21-day study cycle . Cyclophosphamide give 1 hour . Vincristine give 15 minute . Doxorubicin also give 15 minute . The start dose vorinostat may change On Days 1-5 cycle , take prednisone tablet mouth . If begin experience severe intolerable side effect , study drug schedule may stop 3 week . If side effect improve , may able receive study drug , either low dose vorinostat take vorinostat three time daily , may take twice day instead . The chemotherapy drug ( cyclophosphamide , doxorubicin , vincristine , prednisone ) may also lower depend side effect experience . If continue severe intolerable side effect low dose vorinostat chemotherapy , take study . Study Visits : On Day 1 cycle , follow test procedure perform : - Your medical history record , include drug take . - You ask side effect may experience . - You physical exam , include measurement vital sign weight . - Blood ( 5 teaspoon ) draw routine test . - Your performance status record . On Day 1 Cycle 2 ECG . On Day 1 Cycle 3 follow test procedure perform doctor think necessary : - You CT and/or PET scan check status disease . - You may bone marrow aspirate and/or biopsy check status disease . Length Study : You receive study drug 6 cycle . You may take study early disease get bad severe intolerable side effect occur . End-of-Study Visit : If go study treatment reason , end-of-study visit within 4 week last dose study drug start new treatment . At visit , follow test procedure perform : - You physical exam , include measurement vital sign . - Your performance status record . - You ask side effect may experience . - Blood ( 5 teaspoon ) draw routine test . - You CT scan PET scan check status disease . - If skin lesion begin study , skin lesion photograph . - If doctor think need , bone marrow biopsy and/or aspirate . Follow-up Visits : After study treatment , follow-up visit . You go visit every 3 month the1st year , every 4 month 2nd 3rd year , every 6 month 4th 5th year . After , return 1 time year unless lymphoma return . The following test procedure perform : - You physical exam , include measurement vital sign . - Your performance status record - You ask side effect may experience . - Blood ( 5 teaspoon ) draw routine test . - You CT scan PET scan check status disease . - If skin lesion begin study , skin lesion photograph . - If doctor think need , bone marrow biopsy and/or aspirate . This investigational study . Vorinostat FDA approve commercially available treatment cutaneous T-cell lymphoma come back responded prior therapy . CHOP currently FDA approve treatment patient NHL . The use vorinostat combination CHOP patient T-cell NHL investigational . Up 52 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Patients must new diagnosis Tcell NHL eligible histology include : Peripheral Tcell lymphoma ( unspecified ) , CD 30 + anaplastic large cell lymphoma ( ALK ) ( ALK1 positive ALK1 negative ) , angioimmunoblastic Tcell lymphoma , intestinal Tcell lymphoma , subcutaneous panniculitic Tcell lymphoma . 2 . Patients eligible blood marrow transplant receive treatment maximal reduction tumor bulk . A minimum four cycle therapy give evaluation hematopoetic stem cell transplant . 3 . Patients must biopsy proven disease include bone marrow and/or lymph node ( cutaneous disease exclude ) 4 . Patient must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . 5 . Patients must age 18 year old above.There dose adverse event data currently available use vorinostat patient &lt; 18 year age , child exclude study may eligible future pediatric phase 2 combination trial . 6 . There Patients required adequate bone marrow reserve indicate : Absolute neutrophil count ( ANC ) &gt; /= 1000/mm^3 , Platelets &gt; /= 50,000/mm3 , Hemoglobin &gt; /= 8g/dL . If bone marrow involvement lymphoma minimum level count require . 7 . Patients must adequate liver function indicate : Bilirubin &lt; /= 1.5 time upper limit normal ( ULN ) , Alanine transaminase ( ALT ) &lt; /=2 time ( ULN ) aspartate transaminase ( AST ) &lt; /= 2 time ULN . These value must obtain within two week protocol entry . 8 . Patients required adequate renal function indicate serum creatinine &lt; /= 2.5 mg/dL . This value must obtain within two week protocol entry . 9 . Left ventricular ejection fraction must evaluate nuclear medicine scan echocardiography measure &gt; /= 50 % . 10 . Concomitant steroid may continue provide used symptom management treatment lymphoma . 11 . Male patient must agree use barrier method contraception agree abstain heterosexual activity duration study 12 . Female patient must willing use two adequate barrier method contraception prevent pregnancy agree abstain heterosexual activity throughout study post menopausal ( free menses &gt; two year surgically sterilize ) . 13 . Female patient childbearing potential must negative serum pregnancy test ( Beta human chorionic gonadotropin ( hCG ) ) within 72 hour receive first dose vorinostat . 14 . Patients must ability able give inform consent . 1 . 1 . Patients ) Tcell lymphoma skin involvement exclude evidence systemic disease b ) Tcell prolymphocytic leukemia ( TPLL ) c ) Tcell large granular lymphocytic leukemia ) Primary cutaneous CD30+ disorder : anaplastic large cell lymphoma lymphomatoid papulosis e ) Angiocentric/nasal type T/Natural Killer ( NK ) cell lymphoma f ) Hepatosplenic gammadelta Tcell lymphoma 2 . Patients active Hepatitis B and/or Hepatitis C infection . 3 . Patients know HIV infection exclude . ) These patient exclude secondary potential target activate Tcells , population patient already risk Tcell depletion , would contraindication therapy . 4 . Patients active infection require specific antiinfective therapy eligible sign infection resolve . 5 . Patients preexist cardiovascular disease require ongoing treatment . This include : ) Congestive heart failure , b ) Severe CAD , c ) Cardiomyopathy , ) Uncontrolled cardiac arrhythmia , e ) Unstable angina pectoris , f ) Recent MI ( within 6 month ) . 6 . Patients prior exposure either vorinostat ( include histone deacetylase ( HDAC ) inhibitor except valproic acid ) anthracyclines : ) Patients received valproic acid ( VPA ) treatment seizure may enrol study , must receive VPA within 30 day study enrollment . 7 . Patients pregnant breastfeeding . ) Effects treatment fetus young child unknown time . 8 . Patients invasive solid tumor malignancy past five year except nonmelanoma skin cancer cervical carcinoma situ ductal/lobular carcinoma situ breast currently without evidence disease . 9 . Patients undergoing antineoplastic chemotherapy , radiation , hormonal ( exclude contraceptive ) immunotherapy , investigational medication within past four week . 10 . Patients deep vein thrombosis within three month . 11 . Patient concurrent use complementary alternative medicine . 12 . Patients psychiatric illness and/or social situation would limit compliance study medication requirement . 13 . Patients grade 2 neuropathy . 14 . Patients known central nervous system ( CNS ) lymphoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>SAHA</keyword>
	<keyword>Vorinostat</keyword>
	<keyword>Suberoylanilide Hydroxamic Acid</keyword>
	<keyword>MSK-390</keyword>
	<keyword>CHOP</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>AD</keyword>
	<keyword>Hydroxydaunomycin hydrochloride</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Untreated T-cell</keyword>
	<keyword>T-cell NHL</keyword>
	<keyword>Peripheral T-cell lymphoma</keyword>
	<keyword>PTCL</keyword>
	<keyword>CD 30</keyword>
	<keyword>Anaplastic large cell lymphoma</keyword>
	<keyword>Angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>Intestinal T-cell lymphoma</keyword>
	<keyword>Subcutaneous panniculitic T-cell lymphoma</keyword>
</DOC>